To investigate if the phosphorylation pattern in endothelial cells follows what is known for paradoxical activation of BRAF in melanoma cells, we added PLX8394, an inhibitor designed to avoid paradoxical activation, and indeed PLX8394-treated samples did not show elevated pERK levels in either cell type. The gene discussed is BRAF; the disease is melanoma.